SGLT-2 inhibitors and GLP-1 receptor agonists for Type 2 diabetes

Acad Emerg Med. 2024 Apr;31(4):408-411. doi: 10.1111/acem.14895. Epub 2024 Mar 17.

Authors

Esteban Davila¹, James McCormack²

Affiliations

¹ Department of Emergency Medicine, New York City Health + Hospitals/Kings County, Brooklyn, New York, USA.
² Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.

PMID: 38494877
DOI: 10.1111/acem.14895

No abstract available

Keywords: GLP‐1 receptor agonist; SGLT‐2 inhibitor; diabetes; metformin.

Publication types

Review

MeSH terms

Diabetes Mellitus, Type 2* / drug therapy
Glucagon-Like Peptide-1 Receptor Agonists*
Humans
Hypoglycemic Agents / adverse effects
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Glucagon-Like Peptide-1 Receptor Agonists
Hypoglycemic Agents
Sodium-Glucose Transporter 2 Inhibitors